Product Pathways - Tyrosine Kinase / Adaptors
EphB6 Antibody #12560
|12560S||100 µl (10 western blots)||---||In Stock||---|
|12560||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Specificity / Sensitivity
EphB6 antibody recognizes endogenous levels of total EphB6 protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala927 of human EphB6 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Western blot analysis of extracts from 293 cells, untransfected (-) or transfected with EphB6 overexpression vector (+), using EphB6 Antibody.
EphB6 is a kinase-defective receptor and member of the ephrin-B family of transmembrane proteins (1). Although lacking kinase activity, EphB6 can regulate cellular functions through its interaction with adaptor proteins and other Eph family members (2). In hematopoietic cells, EphB6 is specifically expressed in the T cell population (3) and functions as an important regulator of T cell receptor (TCR) mediated signaling. Upon binding with its ephrin-B1 or ephrin-B2 ligand, EphB6 modulates TCR activity through inhibition of JNK signaling, reduction of CD25 expression, and decreased IL-2 secretion (4). Reduced levels of cell proliferation and cytokine secretion are seen in EphB6 knock-out mice relative to wild type (5). In conjunction with EphB3 receptor activation, EphB6 suppresses Fas receptor induced apoptosis by triggering the Akt activation pathway (6). Research indicates that decreased EphB6 expression is associated with a higher degree of metastasis in various cancers, including breast cancer (7), lung cancer (8), and neuroblastoma (9). EphB6 is thought to reduce cancer invasiveness through its effect on cell adhesion and migration. Following EphrinB1 ligand binding, EphB6 is phosphorylated by kinases such as Src and another active EphB kinase (2, 10, 11). Phosphorylated EphB6 forms a stable complex with Cbl and initiates Cbl inhibition of cell adhesion (2,11). EphB6 regulates signal transduction through direct interaction with other active Eph receptor kinases, sequestering these EphB6-bound receptors and inhibiting typical signal transduction function (12).
- Gurniak, C.B. and Berg, L.J. (1996) Oncogene 13, 777-86.
- Freywald, A. et al. (2002) J Biol Chem 277, 3823-8.
- Shimoyama, M. et al. (2000) Growth Factors 18, 63-78.
- Freywald, A. et al. (2003) J Biol Chem 278, 10150-6.
- Luo, H. et al. (2004) J Clin Invest 114, 1762-73.
- Maddigan, A. et al. (2011) J Immunol 187, 5983-94.
- Fox, B.P. and Kandpal, R.P. (2006) Biochem Biophys Res Commun 340, 268-76.
- Müller-Tidow, C. et al. (2005) Cancer Res 65, 1778-82.
- Tang, X.X. et al. (2000) Proc Natl Acad Sci U S A 97, 10936-41.
- Matsuoka, H. et al. (2005) J Biol Chem 280, 29355-63.
- Truitt, L. et al. (2010) Cancer Res 70, 1141-53.
- Fox, B.P. and Kandpal, R.P. (2011) Cancer Genomics Proteomics 8, 185-93.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.